Katarina LeBlanc

2.6k citations

21 papers · 1.6k indexed · 1 hit paper · h-index 16

Genetics top 0.5%
- Mesenchymal stem cell research 7
Hematology top 5%
- Hematopoietic Stem Cell Transplantation 7
- Acute Myeloid Leukemia Research 3
Urology top 5%
Immunology top 10%
- Immune Cell Function and Interaction 3
Surgery top 10%
- Tissue Engineering and Regenerative Medicine 2
Oncology
- Polyomavirus and related diseases 3
Epidemiology
- Cytomegalovirus and herpesvirus research 3
Physiology
- Biomedical Ethics and Regulation 2

Co-authors: Olle Ringdén Ida Rasmusson Björn Sundberg Iván Martín Jacques Galipeau Jan A. Nolta Donald G. Phinney Mauro Krampera
Cited by: Genetics Hematology Urology
Journals: American Journal of Obstetrics and Gynecology (1 paper)Experimental Cell Research (1 paper)British Journal of Haematology (1 paper)
Partner nations: Sweden United States Italy

In The Last Decade

Katarina LeBlanc

21 papers receiving 1.5k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Katarina LeBlanc

Since Specialization

Citations

This map shows the geographic impact of Katarina LeBlanc's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katarina LeBlanc with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katarina LeBlanc more than expected).

Fields of papers citing papers by Katarina LeBlanc

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katarina LeBlanc. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katarina LeBlanc. The network helps show where Katarina LeBlanc may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Katarina LeBlanc, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Katarina LeBlanc Line = papers co-authored together Katarina LeBlanc links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Mesenchymal stromal cell variables influencing clinical potency: the impact of viability, fitness, route of administration and host predisposition Cytotherapy ·Jacques Galipeau,Mauro Krampera,Katarina LeBlanc,Jan A. Nolta,Donald G. Phinney,Yufang Shi,Karin Tarte,Sowmya Viswanathan,Iván Martín	2021	48
2	The Coronavirus Pandemic: A Pitfall or a Fast Track for Validating Cell Therapy Products? Stem Cells and Development ·Maroun Khoury,Laertis Ikonomou,Massimo Dominici,Katarina LeBlanc,Bruce L. Levine,Daniel J. Weiss	2020	8
3	Treatment of vocal fold scarring with autologous bone marrow-derived human mesenchymal stromal cells—first phase I/II human clinical study Stem Cell Research & Therapy ·Stellan Hertegård,Srinivasa Rau Nagubothu,Emma Malmström,Katarina LeBlanc	2020	29
4	Cell-based therapies for coronavirus disease 2019: proper clinical investigations are essential Cytotherapy ·Maroun Khoury,Patrícia R. M. Rocco,Donald G. Phinney,Mauro Krampera,Iván Martín,Sowmya Viswanathan,Jan A. Nolta,Katarina LeBlanc,Jacques Galipeau,Daniel J. Weiss	2020	34
5	Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT®) Mesenchymal Stromal Cell committee position statement on nomenclaturebreakdown → Cytotherapy ·Sowmya Viswanathan,Yufang Shi,Jacques Galipeau,Mauro Krampera,Katarina LeBlanc,Iván Martín,Jan A. Nolta,Donald G. Phinney,Luc Sensebé	2019	542
6	Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations Haematologica ·Christian Scharenberg,Valentina Giai,Andrea Pellagatti,Leonie Saft,Marios Dimitriou,Monika Jansson,Martin Jädersten,Alf Grandien,Iyadh Douagi,Donna Neuberg,Katarina LeBlanc,Jacqueline Boultwood,Mohsen Karimi,Sten Eirik W. Jacobsen,Petter Woll,Eva Hellström‐Lindberg	2016	29
7	Immunogenicity of virosomal adjuvanted trivalent influenza vaccination in allogeneic stem cell transplant recipients Transplant Infectious Disease ·Aditya Ambati,Sigrun Einarsdottir,Isabelle Magalhaes,Thomas Poiret,R. Bodenstein,Katarina LeBlanc,Mats Brune,Markus Maeurer,Per Ljungman	2015	16
8	Different impact of intermediate and unfavourable cytogenetics at the time of diagnosis on outcome of de novo AML after allo-SCT: a long-term retrospective analysis from a single institution Medical Oncology ·Hareth Nahi,Mats Remberger,Maciej Machaczka,Johanna Ungerstedt,J. Mattson,Olle Ringdén,Katarina LeBlanc,Per Ljungman,H Hägglund	2012	1
9	Treatment with mesenchymal stromal cells is a risk factor for pneumonia‐related death after allogeneic hematopoietic stem cell transplantation European Journal Of Haematology ·Ulrica Forslöw,Ola Blennow,Katarina LeBlanc,Olle Ringdén,Britt Gustafsson,Jonas Mattsson,Mats Remberger	2012	63
10	Donor cell‐derived acute myeloid leukemia after second allogenic cord blood transplantation in a patient with Fanconi anemia Pediatric Transplantation ·Britt Gustafsson,Jacob Moell,Katarina LeBlanc,Gisela Barbany,Stefan Söderhäll,Jacek Winiarski	2011	11
11	Targeted monitoring of patients at high risk of post‐transplant lymphoproliferative disease by quantitative Epstein–Barr virus polymerase chain reaction Transplant Infectious Disease ·Hamdy Omar,H Hägglund,Åsa Gustafsson‐Jernberg,Katarina LeBlanc,Jonas Mattsson,Mats Remberger,Olle Ringdén,E. Sparrelid,Mikael Sundin,Jacek Winiarski,Yun Zhang,Per Ljungman	2009	59
12	Risk factors for acute graft-versus-host disease grades II–IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors—a single centre study Bone Marrow Transplantation ·Mats Remberger,Jonas Mattsson,Zeinab Hassan,Niklas Karlsson,Katarina LeBlanc,B. Omazic,Mantas Okas,Darius Sairafi,Olle Ringdén	2007	27
13	Human mesenchymal stem cells do not differentiate into cardiomyocytes in a cardiac ischemic xenomodel Annals of Medicine ·Karl‐Henrik Grinnemo,Agneta Månsson‐Broberg,Katarina LeBlanc,Matthias Corbascio,Eva Wärdell,Anwar J. Siddiqui,Xiaojin Hao,Christer Sylvén,Göran Dellgren	2006	58
14	Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced‐intensity conditioning regimens British Journal of Haematology ·Mats Merup,Vladimir Lazarević,Hareth Nahi,Björn Andréasson,Claes Malm,Lars Nilsson,Mats Brune,Katarina LeBlanc,Jack Kutti,Gunnar Birgegård,(unknown)	2006	41
15	Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms Experimental Cell Research ·Ida Rasmusson,Olle Ringdén,Björn Sundberg,Katarina LeBlanc	2005	415
16	Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia Biology of Blood and Marrow Transplantation ·Anna Nordlander,Jonas Mattsson,Olle Ringdén,Katarina LeBlanc,Britt Gustafsson,Per Ljungman,Petter Svenberg,Johan Svennilson,Mats Remberger	2004	41
17	Allogenic stem cell transplantation for nonmalignant disorders using matched unrelated donors Biology of Blood and Marrow Transplantation ·Petter Svenberg,Mats Remberger,Johan Svennilson,Jonas Mattsson,Katarina LeBlanc,Britt Gustafsson,J Aschan,Lisbeth Barkholt,Jacek Winiarski,Per Ljungman,Olle Ringdén	2004	14
18	G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II–IV Bone Marrow Transplantation ·Mats Remberger,N Naseh,J Aschan,Lisbeth Barkholt,Katarina LeBlanc,P Svennberg,Olle Ringdén	2003	57
19	Donor chimerism across full allogenic barriers achieved by in utero transplantation of fetal mesenchymal stem cells in a case of osteogenesis imperfecta American Journal of Obstetrics and Gynecology ·L. M. R. Westgren,Göran Annerén,Ove Axelssön,Uwe Evald,Katarina LeBlanc,Olle Ringdén	2003	5
20	No evidence for an altered mRNA expression or protein level of haematopoietic cell phosphatase in CD34⁺ bone marrow progenitor cells or mature peripheral blood cells in polycythaemia vera European Journal Of Haematology ·Patrik Andersson,Katarina LeBlanc,B‐Å. Eriksson,Jessica Samuelsson	1997	21

About Katarina LeBlanc

Katarina LeBlanc is a scholar working on Genetics, Hematology and Immunology, having authored 21 papers that have together received 1.6k indexed citations. Recurring topics across this work include Mesenchymal stem cell research (7 papers), Hematopoietic Stem Cell Transplantation (7 papers), Acute Myeloid Leukemia Research (3 papers), Immune Cell Function and Interaction (3 papers), Polyomavirus and related diseases (3 papers), Cytomegalovirus and herpesvirus research (3 papers), Biomedical Ethics and Regulation (2 papers) and Tissue Engineering and Regenerative Medicine (2 papers). The work is most often cited by research in Genetics (1.0k citations), Hematology (339 citations) and Urology (74 citations). Katarina LeBlanc has collaborated with scholars based in Sweden, United States and Italy. Frequent co-authors include Olle Ringdén, Ida Rasmusson, Björn Sundberg, Iván Martín, Jacques Galipeau, Jan A. Nolta, Donald G. Phinney, Mauro Krampera, Sowmya Viswanathan and Yufang Shi. Their work appears in journals such as American Journal of Obstetrics and Gynecology, Experimental Cell Research and British Journal of Haematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact